Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost

Abstract

Purpose

Patient satisfaction is important in the treatment of glaucoma. Suboptimal compliance and impaired long-term outcome are a likely result of poor tolerability. The present multicentre, international, transverse, epidemiological survey was conducted to assess the satisfaction of patients who had received preservative-free latanoprost (PFL) for at least 3 months.

Patients and Methods

A total of 1872 patients from 6 European countries, treated with PFL for at least 3 months, were included in this survey. Prior to PFL treatment, patients were to be treatment naïve or currently treated for their glaucoma. During a single routine consultation, patients completed a questionnaire concerning global satisfaction and satisfaction based on tolerability.

Results

In total, 76.2% had been previously treated; 69.4% had received preserved and 6.8% preservative-free (PF) topical treatment. After 3 months of PFL treatment, a large majority of patients (95.3%) were satisfied or very satisfied with their PFL treatment and were, overall, significantly (p<0.0001) more satisfied with PFL than with their previous treatment; 4.2% were either unsatisfied or very unsatisfied. Overall, 97.3% of originally treatment-naïve patients were satisfied (50.1%) or very satisfied (47.2%) with their PFL. Ocular surface disease was diagnosed in 9.2% of patients (n=173) and was mainly mild (76.9%). Patient satisfaction with PFL was very high. 

Conclusion

PFL may be considered a valuable first-choice treatment in glaucoma patients.

Keywords:

• glaucoma
• prostaglandin
• preservative-free latanoprost
• patient satisfaction
• tolerability
• tear substitutes
• intra-ocular pressure
• ocular surface disease
• conjunctival hyperaemia

Acknowledgments

The authors acknowledge the participation of the PASSY study team and of their patients and the writing assistance of Karl Patrick Göritz, SMWS, France.

Disclosure

Prof. Carl Erb received consultancies from Aerie, Alcon, Allergan, Bayer, Bausch&Lomb, Thea, Santen, OmniVision, Ophtaprotect, Oculus, Glaukos and Zeiss. Prof. Ingeborg Stalmans received consultancies and research grants from Aerie, Alcon, Allergan, EyeD Pharma, EyeTechCare, Horus Pharma, Oculis, Santen, Laboratoires Théa, and Zeiss. Prof. Milko Iliev received consultancies and research grants from Thea, Santen, and Allergan. Prof. Francisco José Muñoz-Negrete received consultancies and research grants from Alcon, Avizor, Bayer, Esteve, Laboratoires Théa, and Santen. The authors report no other conflicts of interest in this work.

Additional information

Funding

The study was funded by Laboratoires Théa, Clermont-Ferrand, France.